Pharmaceutical News and Articles
Print Email

Lucentis (ranibizumab injection)

February 1, 2007

Audience: Ophthalmological healthcare professionals

Indication: Treatment of patients with neovascular (wet) age-related macular degeneration
[Posted 02/01/2007] Genentech informed healthcare professionals of preliminary safety information from a planned interim analysis in an ongoing study (SAILOR) which confirmed the higher incidence of stroke in the 0.5 mg dose group compared to the 0.3 mg dose group (1.2% versus 0.3%, respectively; P=0.02) of patients with neovascular (wet) age-related macular degeneration who received intravitreal Lucentis. The rates of stroke for both dose groups are lower than the rates seen in the controlled clinical trials and included in the approved labeling. The planned frequency of dosing was not the same as that described in the approved labeling. This comparison was one of many made during this interim analysis.

[January 24, 2007 – Letter – Genentech]

Latest FDA MedWatch Alerts...

FDA MedWatch Alerts Archive

2009: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2002: Feb | Mar | Apr | May | Jun | Jul | Sep | Oct | Nov

More News Resources

Daily MedNews
Pharma Industry News
New Drug Applications
New Drug Approvals
Clinical Trial Results
Generic Drug Approvals
Monthly Update Archive

Services
Home
A to Z Drug List
Drugs by Condition
Drug Side Effects
Natural Products
Community Forums
Interactive Tools
Pill Identifier
Interactions Checker
MedNotes beta
Support Groups beta
Drug Image Search
Phonetic Search
News & Articles
Latest Drug News
FDA Drug Alerts
New Drug Approvals
New Drug Applications
Clinical Trial Results
Medical Encyclopedia
News FeedsRSS Feeds
Health Professionals
Professional Resources
Drugs by Classification
Patient Care Notes
Drug Imprint Codes
Medical Dictionary
Animal Medicine
Veterinary Drugs
Advertise Here
Recent Searches
Altace
Cubicin
Crestor
Flonase
Methotrexate
Amevive
Fioricet
Vasovist
Niacin
Plan B One-Step
Mozobil
Neupro
Propecia
Xenical
Extavia
Femhrt
Faslodex
Trilipix
Vectibix
Atarax
Angeliq
Exubera
Avalide
Hoodia
Aleve
Recently Approved
Lysteda
Istodax
Pennsaid
Arzerra
Votrient
Twynsta
Cervarix
Berinert
Stelara
Folotyn
More...

Subscribe to our popular newsletter containing a regular roundup of medication news, alerts and new drug approvals.


MedNotes
Most Popular Internet Searches
Lipitor
Viagra
Zoloft
Crestor
 Cialis
Wellbutrin
Effexor
Celebrex
 Levitra
Neurontin
Paxil
Zocor
Advertisement
Latest Drug Information Updates

Lysteda
Lysteda (tranexamic acid) is an antifibrinolytic agent for the treatment of women with menorrhagia, heavy menstrual bleeding (HMB), and its accompanying symptoms.

Pennsaid
Pennsaid is a topical non-steroidal anti-inflammatory drug (NSAID) used for the treatment of signs and symptoms of osteoarthritis of the knee.

Istodax
Istodax (romidepsin) a histone deacetylase (HDAC) inhibitor indicated the treatment of cutaneous T-cell lymphoma.

Cervarix
Cervarix (human papillomavirus bivalent (types 16 and 18) is a is a preventative cervical cancer vaccine for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic human papillomavirus (HPV) types 16 and 18 in girls and young women (aged 10-25).

Votrient
Votrient (pazopanib) is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma.

Arzerra
Arzerra (ofatumumab) is a CD20-directed cytolytic monoclonal antibody indicated for the treatment of patients with chronic lymphocytic leukemia.

Twynsta
Twynsta (telmisartan/amlodipine) is an angiotensin II receptor blocker (ARB) and a dihydropyridine calcium channel blocker (DHP-CCB) combination product indicated for the treatment of hypertension alone or with other antihypertensive agents.

Berinert
Berinert (C1-esterase inhibitor (human)) is a plasma derived C1 Esterase Inhibitor indicated for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE) in adult and adolescent patients.

Stelara
Stelara (ustekinumab) is a human monoclonal antibody for the treatment of moderate to severe plaque psoriasis.

Influenza A (H1N1) 2009 Monovalent Vaccine
Influenza A (H1N1) 2009 Monovalent Vaccine is an inactivated influenza virus vaccine indicated for active immunization of persons ages 18 years of age and older against influenza disease caused by pandemic (H1N1) 2009 virus.

Zirgan
Zirgan (ganciclovir ophthalmic gel) is a topical ophthalmic antiviral preparation for the treatment of acute herpetic keratitis (dendritic ulcers).

Vibativ
Vibativ (telavancin) is a bactericidal, once-daily injectable antibiotic for the treatment of complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

Folotyn
Folotyn (pralatrexate) is a folate analogue metabolic inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

Valturna
Valturna is a combination of aliskiren (a direct renin inhibitor) and valsartan (an angiotensin II receptor blocker) indicated for the treatment of high blood pressure.

Bepreve
Bepreve (bepotastine ophthalmic solution) is an antihistamine and mast cell stabilizer for treatment of the symptoms of allergic conjunctivitis.

More...

(web2)